230 likes | 392 Views
Globalisation and Health. Lars Rebien Sørensen, CEO, Novo Nordisk A/S. Globalisation. Expansion. Opportunities. Inequity. Poverty. Divides. Politics. The Dilemmas. Lifestyle and Health. Dilemma: Benefits Drawbacks. The Role of Governments. Dilemma: The ideal welfare state
E N D
Globalisationand Health Lars Rebien Sørensen, CEO, Novo Nordisk A/S
Expansion Opportunities Inequity Poverty Divides Politics
Lifestyle and Health Dilemma: Benefits Drawbacks
The Role of Governments Dilemma: The ideal welfare state The undemocratic regime
Intellectual Property Rights Dilemma: Prerequisite for investments Access in developing countries
The Role of the Health Care Business Dilemma: Corporate citizen Shareholder value
Funding from Business Dilemma: Corporate philantrophy Social investment
Year 1995: 135 mio. Year 2025: 300 mio. Global Increase in Diabetes 350 300 250 200 150 100 50 0 1995 2000 2005 2010 2015 2020 2025
Who will become Diabetic… • more than 10% of the elderly population in the industrialised world • people who are overweight are especially at risk (>20%) • 75% of the increase will take place in the developing countries • the largest increase will hit the 45-60 years age group • diabetes is the fourth commonest cause of death today
People with diabetes … • have 2-4 times increased risk of heart diseases • have 2.5 times increased risk of heart attacks • represent the largest prevalence of blindness among grown-ups • 60-65% have high blood pressure • 60-70% have injuries in the vascular and nervous system, which makes diabetes the most significant reason for amputations
Our Lighthouse Vision Values The Triple Bottom Line
Balancing the Triple Bottom Line Economically viable Socially Responsible Environmentally sound
WHO’s Response • National health strategies • National health care capacity • Best possible pricing • Additional funding
LEAD – Leadership in Education and Access to Diabetes Care The National Diabetes Strategies project The DAWNproject The World Partner Programme Insulin prices in LDCs equal 20% of prices in the rest of the World The World Diabetes Foundation Novo Nordisk’s Response • National health strategies • National health care capacity • Best possible pricing • Additional funding
Trust Licence to Operate Stakeholders Attract Retain History Values
“The point is to see change as anopportunity instead of a threat.” Peter Drucker